KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other Operating Expenses (2016 - 2026)

Biomarin Pharmaceutical has reported Other Operating Expenses over the past 18 years, most recently at $4.0 million for Q1 2026.

  • For the quarter ending Q1 2026, Other Operating Expenses rose 302.71% year-over-year to $4.0 million, compared with a TTM value of $18.1 million through Mar 2026, up 636.91%, and an annual FY2025 reading of $9.0 million, up 292.74% over the prior year.
  • Other Operating Expenses came in at $4.0 million for Q1 2026, down from $9.0 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $111.9 million in Q4 2022 to a low of -$19.9 million in Q4 2023.
  • Median Other Operating Expenses over the past 5 years was $1.3 million (2024), compared with a mean of $8.0 million.
  • The sharpest move saw Other Operating Expenses surged 1172.02% in 2022, then crashed 1103.38% in 2023.
  • Over 5 years, Other Operating Expenses stood at $111.9 million in 2022, then tumbled by 117.78% to -$19.9 million in 2023, then skyrocketed by 65.47% to -$6.9 million in 2024, then surged by 230.94% to $9.0 million in 2025, then plummeted by 55.97% to $4.0 million in 2026.
  • Per Business Quant, the three most recent readings for BMRN's Other Operating Expenses are $4.0 million (Q1 2026), $9.0 million (Q4 2025), and $5.1 million (Q3 2025).